Trial Profile

A Phase 2a Study to Evaluate the Safety and Tolerability of Two Repeated Doses of GM-2505 at a 2-Week Interval in Patients With Major Depressive Disorder.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GM 2505 (Primary)
Indications Major depressive disorder
Focus Adverse reactions
Sponsors Gilgamesh Pharmaceuticals

Most Recent Events

27 May 2025 According to a Gilgamesh Pharmaceuticals media release, data from this trial to be presented at the American Society of Clinical Psychopharmacology Annual Meeting in Scottsdale, Arizona, May 27 - May 29, 2025
27 May 2025 Results presented in the Gilgamesh Pharmaceuticals Media Release.
06 Mar 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com